M. Chesi

Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

G. Mulligan, P. L. Bergsagel, R. Fonseca, 2011, Leukemia.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

B. Barlogie, J. Shaughnessy, G. Morgan, 2009, Leukemia.

associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

H. Avet-Loiseau, R. Bailey, Wm, 2001 .

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

P. L. Bergsagel, K. M. Kortuem, Jessica E. Schmidt, 2013, Leukemia.

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

P. L. Bergsagel, P. Atadja, M. Doyle, 2013, Cell Death and Disease.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

P. L. Bergsagel, M. Colonna, Camille Guillerey, 2015, The Journal of clinical investigation.

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution

G. Ahmann, P. L. Bergsagel, R. Fonseca, 2007, Leukemia.